Insiders' dealing Report of transactions with shares and related securities of NeuroSearch by persons discharging managerial responsibilities and persons/companies closely associated with these Pursuant to section 28a of the Danish Act on Securities Trading, NeuroSearch A/S (NEUR.CO) shall make public, transactions with shares and related securities of NeuroSearch A/S by persons discharging managerial responsibilities and persons/companies closely associated with these. Name: Nicholas Waters Reason: CEO, NeuroSearch Sweden AB Issuer and ID code / ISIN: NeuroSearch A/S / DK0010224666 Transaction: Sale of shares Trading date: 27 August 2008 Market: The OMX Nordic Exchange Copenhagen A/S Number (pcs): 6,000 Market value (DKK): 1,595,700 Contact person: Anita Milland, Vice President, CFO, telephone: +45 2016 3432 NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen A/S. The company's core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial share of its activities is partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with, among others, Abbott and Astellas. NeuroSearch's drug pipeline comprises 14 clinical (Phase I-III) development programmes: ACR16 for Huntington's disease (Phase III), tesofensine for obesity and in Type 2 diabetes (Phase III in preparation), NS2359 for depression (Phase II) and ADHD (Phase II) in partnership with GSK, ABT-894 for ADHD (Phase II) and pain (Phase II) in partnership with Abbott, ACR16 for schizophrenia (Phase I) in partnership with Astellas, ACR325 for Parkinson's disease (Phase II in preparation) and bipolar disorder (Phase II in preparation), ABT-107 and ABT-560 for the treatment of various CNS disorders - both (Phase I) in collaboration with Abbott, NSD-644 for pain (Phase I) in partnership with GSK, ACR343 for Parkinson's disease (Phase I) and NSD-788 for anxiety/depression (Phase I). In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.
Report of transactions with shares and related securities of NeuroSearch by persons discharging managerial responsibilities and persons/companies closely associated with these
| Source: NTG Nordic Transport Group A/S